Entecavir plus tenofovir vs. lamivudine/telbivudine plus adefovir in chronic hepatitis B patients with prior suboptimal response
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Woo, Hyun Young | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Bae, Si Hyun | - |
dc.contributor.author | Kim, Chang Wook | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Tak, Won Young | - |
dc.contributor.author | Kim, Dong Joon | - |
dc.contributor.author | Kim, In Hee | - |
dc.contributor.author | Heo, Jeong | - |
dc.contributor.author | Ahn, Sang Hoon | - |
dc.date.accessioned | 2021-08-11T08:34:22Z | - |
dc.date.available | 2021-08-11T08:34:22Z | - |
dc.date.issued | 2020-07 | - |
dc.identifier.issn | 2287-2728 | - |
dc.identifier.issn | 2287-285X | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/2683 | - |
dc.description.abstract | Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomized to receive a new treatment (ETV+TDF, n=45) or maintained on the same treatment (LAM/LdT+ADV, n=46) for 48 weeks. Patients with baseline ADV resistance were excluded. Results: Compared to LAM/LdT+ADV group, ETV+TDF group had more patients with a virologic response (42/45 [93.33%] vs. 3/46 [6.52%], P<0.001) and had a greater mean reduction in serum HBV DNA level from baseline (-4.16 vs. -0.37 log(10 )IU/mL, P<0.001). Multivariate analysis indicated that high baseline HBV DNA level (P=0.005) and LAM/LdT+ADV maintenance therapy (P=0.001) were negatively associated with virologic response. At week 48, additional ADV- or ETV-associated mutations were cleared in ETV+TDF group, but such mutations were present in 4.3% of patients in LAM/ LdT+ADV group (P=0.106). The two groups had similar rates of adverse events. Conclusions: ETV+TDF combination treatment led to a significantly higher rate of virologic response compared to LAM/ LdT+ADV combination treatment in patients with LAM-resistant HBV who had suboptimal responses to LAM/LdT+ADV regardless of HBV genotypic resistance profile (NCT01597934). | - |
dc.format.extent | 12 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 대한간학회 | - |
dc.title | Entecavir plus tenofovir vs. lamivudine/telbivudine plus adefovir in chronic hepatitis B patients with prior suboptimal response | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3350/cmh.2019.0044n | - |
dc.identifier.scopusid | 2-s2.0-85087392010 | - |
dc.identifier.wosid | 000546547500014 | - |
dc.identifier.bibliographicCitation | Clinical and Molecular Hepatology, v.26, no.3, pp 352 - 363 | - |
dc.citation.title | Clinical and Molecular Hepatology | - |
dc.citation.volume | 26 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 352 | - |
dc.citation.endPage | 363 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART002602110 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | TERM LAMIVUDINE THERAPY | - |
dc.subject.keywordPlus | RESCUE THERAPY | - |
dc.subject.keywordPlus | HEPATOCELLULAR-CARCINOMA | - |
dc.subject.keywordPlus | VIROLOGICAL RESPONSE | - |
dc.subject.keywordPlus | NAIVE PATIENTS | - |
dc.subject.keywordPlus | RESISTANT | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | DIPIVOXIL | - |
dc.subject.keywordPlus | RISK | - |
dc.subject.keywordAuthor | Entecavir | - |
dc.subject.keywordAuthor | Tenofovir | - |
dc.subject.keywordAuthor | Lamivudine | - |
dc.subject.keywordAuthor | Antiviral drug resistance | - |
dc.subject.keywordAuthor | Adefovir | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.